Lupin Healthcare are committed to supporting the NHS in its goal of becoming net zero by 20401
Through carbon offsetting Lufobec 100/6 pMDI is now certified carbon neutral.2,3
What does this mean and how is it achieved?
All inhalers, including Dry Powder Inhalers (DPIs) have a carbon footprint associated with their manufacture, distribution and use4
Lupin Healthcare have conducted a Life Cycle Assessment to understand the greenhouse gas (GHG) emissions associated with Luforbec 100/6 pMDI. This assessment follows the principles of the Greenhouse Gas Protocol and ISO 14067:2018 and focuses on the embodied GHG emissions of raw materials, the transport of these materials, the manufacture/processing, distribution, use and disposal of Luforbec 100/6 pMDI.2
By understanding the GHG emissions associated with the various stages of Luforbec’s life cycle, we can take steps to reduce these.
We have offset the carbon footprint of Luforbec 100/6 pMDI through supporting global sustainability and environmental projects, making Luforbec 100/6 pMDI a certified carbon neutral product.2,3
References: 1. NHS Delivering Net Zero Health Service https://www.england.nhs.uk/greenernhs/a-net-zero-nhs/ Accessed June 2022. 2. Certification of carbon neutrality for Luforbec 100/6 pMDI. 3. Carbon Footprint Limited, Carbon Assessment Report 2022. Data on File. 4. MIMS: Inhaler Carbon Emissions. https://www.mims.co.uk/inhaler-carbon-emissions/respiratory-system/article/1739635. Accessed: June 2022.
LUP-CORP-005s DOP: December 2020